News & Updates

A higher placental weight (PW) often results in higher offspring BMI, but its effect lessens by the age of 9 years, reveals a study.

Treatment with the investigational oral orexin receptor 2–selective agonist oveporexton appears to yield improvements in wakefulness, sleepiness, and cataplexy in individuals with narcolepsy type 1, according to the results of a phase II study.

Factors such as APOE4 allele, dementia onset before age 60 years, Alzheimer’s disease (AD) dementia subtype, worse cognition, stroke/transient ischaemic attack (TIA), and Parkinson’s disease (PD) all contribute to a heightened risk of late-onset epilepsy in people with cognitive decline, as reported in a study.

Fremanezumab appears to provide a two-for-one benefit in patients with migraine and comorbid depressive disorder, with data from the UNITE study showing that the drug helped reduce migraine days and lift mood.

Among women with a history of pregnancy loss, prior exposure to Chlamydia trachomatis poses an increased risk of miscarriage, as reported in a study.

Treatment with targeted-release budesonide formulation preserves kidney function and reduces proteinuria in patients with IgA nephropathy (IgAN) independent of baseline eGFR, and this benefit is seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period, according to a subanalysis of the phase III NeflgArd study presented at the ERA annual meeting.